FGFR3 | ApexOnco - Clinical Trials news and analysis

x

“It's very intuitive and always up-to-date”

Monika Vogelmann

Head of Market Insights Oncology Europe

Daiichi Sankyo

Click here for more information

Conferences Trial results

25 October 2024

Triple meeting 2024 – Tyra’s targeted FGFR3 push

The company reckons it’s got what it takes to hit the right member of the FGFR family.

Subscribe to FGFR3